Stryker (SYK -0.1%) has launched Surpass Evolve Flow Diverter, a 64-wire cobalt chromium flow diverter designed to re-direct blood flow and promote aneurysm healing.
Since its launch in Europe last year, Surpass Evolve has been approved in 45+ countries.
Mark Paul, president of Stryker’s Neurovascular division, added, “Surpass Evolve is our fourth PMA approval and second flow diverter approved by the FDA in the last two years.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.